Lifecare (LIFE)

[TekBot]

Lifecare newsletter April 2022

Bergen, Norway 4 April 2022

Demonstration of nano-scale dispensing of biochemical solutions on the Sencell chip and an article in the Norwegian Technical Weekly. Upcoming events and an operational update.
…

Vis børsmeldingen

Read more in the Lifecare April newsletter:
https://lifecare.no/news/information-from-lifecare-april-2022/

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 04.04.22 at 09:00 CET.

Kilde

[TekBot]

Invitation to Lifecare Annual Report webcast

Bergen, Norway 19 April 2022

Lifecare AS’ management team will host an online presentation of the 2021 annual results on Thursday 21 April 2022.
…

Vis børsmeldingen

The webcast will be for all shareholders and interested parties at 13:00 – 14:00 CET. There will be a Q&A session following the management presentation. The link to the webcast will be available in the Investors section: Webcast Annual Report 2021 - Lifecare

The annual report and the presentation material will be available on https://newsweb.oslobors.no/ and in the Investors section https://lifecare.no on the reporting day.

You can post questions during the event or send them in advance to: kine.hereid@lifecare.no

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 19.04.2022 at 14:50 CET.

Kilde

[TekBot]

Issuance of new shares to primary insider – in accordance with share purchase agreement prev. announced

Bergen, Norway 20 April 2022

Islay Venture GmbH (“Islay), a company closely related to Lifecare’s Chief Scientific Officer and primary insider Prof. Dr. Dr. med Andreas Pfützner, will subscribe 1.756.876 new shares in Lifecare AS, as part of the previously agreed consideration from Lifecare AS to acquire Lifecare Laboratories GmbH (formely named Pfützner Science and Health GmbH). The acquisition and considerations were previously announced in Newsweb 27 August 2021.
…

Vis børsmeldingen

Lifecare AS will issue shares in Lifecare AS equivalent to a value of EUR 300.000 EUR converted into NOK 2.856.840,- at an exchange rate of NOK 9,5228. The amount will convert into 1.756.876 Lifecare AS new shares at a calculated VWAP-based share price of NOK 1,626091. The share price is based on VWAP 5 consecutive trading days prior to the share purchase agreement’s notarised signature date: 27 January 2022.

Islay currently holds 843.623 shares in Lifecare AS. After the issuance of new shares, Islay will hold a total of 2.600.499 shares in Lifecare AS.

The new shares will be issued based on board authorization granted by the Extraordinary General Meeting of Lifecare 10 September 2021 as registered in the company register 8 November 2021. The share issue is expected to be completed by 30 April 2022.

On this base the Lifecare board of directors has resolved to issue in total 1.756.876 new shares for an aggregated subscription price of NOK 2.856.840. Following the issuance of the new shares, the Company will have 99.741.023 shares outstanding, each with a nominal value of NOK 0.40. Total share capital of the Company will be NOK 39.896.409,20-. The Company’s Articles of Associations will be updated accordingly.

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 20 April 2022 at 20:10 CET.

Kilde

[TekBot]

Annual report 2021 and webcast

Bergen, Norway 21 April 2022

Today, Lifecare 2021 annual report is published. 2021 was marked by several important milestones:
…

Vis børsmeldingen

• Regulatory approval for first-in-human pilot clinical trials
• Restructuring the organization – controlling development operations
• Reinforced Patent Protection and IP
• Successful Capital Increase

The report is subject to approval by the company’s general meeting on 6 May 2022.

Lifecare AS’ management team will host an online presentation of the 2021 annual results today at 13:00 – 14:00 CET. The presentation will also include development outlook and assumptions related to the patient and market potential for Sencell. The report and the presentation are attached to this release and are also available on Lifecare’s website. The basis for the Sencell market potential can be downloaded at SENCELL Market Assumptions and Commercial Potential, April 2022 - Lifecare There will be a Q&A session following the management presentation.

The link to the webcast is available in the Investors section: Webcast Annual Report 2021 - Lifecare. You can post questions during the event or send them in advance to: kine.hereid@lifecare.no

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 21 April 2022 at 11:00 CET.

Kilde

[TekBot]

Lifecare AS: Notification of Annual General Meeting

Bergen, Norway 22 April 2022

The Annual General Meeting (“AGM”) of Lifecare AS will be held on 6 May 2022 at 10:00 CET. Notice of the AGM is enclosed to this announcement.
…

Vis børsmeldingen

The meeting will be conducted as a combined physical and digital meeting. Shareholders who wish to participate and vote at the General Meeting must be registered with a user profile in the meeting portal Orgbrain (www.orgbrain.no). It will be possible to attend the meeting in person or digitally through Orgbrain. Further information about participation and registration appears from the notice.

To save the environment and reduce costs incurred sending the notification by post to the shareholders, please see attached a manual (in Norwegian) on how to receive notices and information electronically instead of by post.

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth Oslo (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 22 April 2022 at 10:45 CET.

Kilde

[TekBot]

Registration of new share capital

Bergen, 03 May 2022

Reference is made to the stock exchange announcement by Lifecare AS (the “Company”) on 20 April 2022 regarding the share issue resolved by the board of directors as part of the previously agreed consideration from Lifecare AS to acquire Lifecare Laboratories GmbH (formely named Pfützner Science and Health GmbH). The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The new share capital of the Company is NOK 39,896,409.20, divided into 99,741,023 shares, each with a nominal value of NOK 0.4
…

Vis børsmeldingen

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information: Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 03 May 2022 at 16:00 CET.

Kilde

[TekBot]

Minutes from Annual General Meeting

Bergen, Norway 06 May 2022

The Annual General Meeting of Lifecare AS was held both digitally and physically on Friday 06 May 2022 on the meeting platform Orgbrain. All proposals on the agenda were adopted, cf. the notification of the Annual General Meeting that was published on Oslo Stock Exchange on 22 April 2022. The complete minutes of the Annual General Meeting are attached and will be available on www.lifecare.no
…

Vis børsmeldingen

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 06 May 2022 at 11.35 CET.

Kilde

[TekBot]

Lifecare Group incentive program established

Bergen, 23 May 2022

On 6 May 2022, the Lifecare Annual General Meeting (AGM) passed a resolution authorizing the Board of Directors to establish an incentive program for employees and consultants in the Lifecare Group. The AGM resolution included an authorization for the Board to increase the share capital by up to 5% of the existing registered share capital for use in an incentive program. On this base, Lifecare’s Board of Directors has decided to establish an incentive program including option grants to the company’s executive management and key employees:
…

Vis børsmeldingen

• Lifecare CEO, Joacim Holter, has been granted a total of 1.496.115 options with performance-based vesting terms.
• Lifecare CSO, Prof. Andreas Pfützner, has been granted a total of 748.058 options with performance-based vesting terms.
• Other key personnel in the Lifecare Group have each been granted 25.000 options that can be vested at the earliest 3 years from the date of grant.

In addition, the Board of Directors has mandated the CEO to grant up to 20.000 options per employee in the Lifecare Group to defined key personnel based on performance target vesting terms. Furthermore, all employees in the Lifecare Group will be invited to participate in a Share Purchase Program with a 25% discount per share and financing based on a payroll deduction over 12 months, for up to 20.000 shares per employee.

All options will be valid for 5 years from the date of grant. Price per share under the incentive program is defined to be based on the volume-weighted average price of the ordinary shares on the principal market for a period of 10 consecutive trading days prior to the date of grant. Assuming 100% participation in the Share Purchase Program, 100% allocation and achievement of option performance targets, as well as the said time factor of three years for the group of key personnel, the execution of the implemented incentive program will have a total scope of 2.604.173 shares, i.e. slightly above 2,5% of the existing registered share capital of Lifecare AS.

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information: Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 23 May 2022 at 21:00 CET.

Kilde

[Salamis]

Ansatte i selskapet skal altså få lov til å bytte lønn for 20 000 rabatterte aksjer. Håper de ansatte også får en (gratis?)klapp på skulderen. Da bør incentivet være komplett.

Tenk å være cfo i dette selskapet og muligens få maks 25 000 opsjoner mens cso/ceo rasker med seg 2,2 av 2,6 mill. Makan til skeivfordeling.

[stAMy]

Dette selskapet er like mye scam den dag i dag som for 2 år siden.

[TekBot]

Mandatory notification of trade

Bergen, Norway 1 June 2022

Primary insider Joacim Holter has bought 25 000 shares at an average price of 3,01 in Lifecare AS.
…

Vis børsmeldingen

Joacim Holter currently holds 272.997 shares in Lifecare AS, and after the trade, Joacim Holter will hold a total of 297 997 shares in Lifecare AS. Joacim Holter also owns shares in Lifecare through his fully owned investment company Cimter AS, 1 331 355 shares.

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 1 June 2022 at 0745 CET.

Kilde

[TekBot]

Lifecare achieves milestone

Bergen, Norway 02 June 2022

In the late hours of June 1st, 2022, the team at Lifecare NanoBioSenors concluded successful, high quality and reproducible in-vitro test results with the miniaturized Sencell sensor for glucose measurement. This is a milestone achievement confirming functionality of Lifecares proprietary technology both in the nanoscale of the miniaturized sensors, as well as the signal readout based on the Nano Tunneling Resistive (NTR) pressure sensing.
…

Vis børsmeldingen

With this achievement Lifecare has reached the first of two major milestones for 1H 2022, the prototype fabrication for clinical trials. While the team at Lifecare NanoBioSensors will ensure manufacturing of sensors for the upcoming first-in-human pilot clinical study, Lifecare Laboratory will prepare the final steps for initiation of the study in June.

For Lifecare it is of particular importance that the current milestone achievement is reached fully based on the internal resources in the Lifecare Group. This is a strong confirmation of the successful strategic reorganization of Lifecare AS initiated in Q2 2021.

Lifecare CSO, Prof. Dr. Dr. Med. Andreas Pfützner, comments: “Reaching this milestone with our new own infrastructure and scientists is a groundbreaking science achievement for Lifecare! Our miniaturized NTR-sensors measure osmotic pressure with the same performance as the large piezo-resistive-sensors that we have used in the previous animal studies. Basic research is herewith accomplished, and we are now executing the last and final development steps required for the first in-human trial within a very short-term future.”

Preparations for the pilot clinical studies still includes both practical and scientific risks, i.e. the complexity of manual production and device sterilization. Based on the project experiences and preparations, Lifecare is confident that these tasks will be solved in accordance with the project plan and consequently lead to the first patient within end of June 2022.

Lifecare CEO, Joacim Holter, comments: “We are very happy to announce the achievement of this critical milestone within the planned scope of time. The core team in the Lifecare Group has worked with dedication and focus, and it is important for us to deliver this result to our solid base of shareholders. We look forward to the tasks ahead of us which we now will approach with renewed energy and confidence based on this practical and scientific milestone achievement”

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 2 June 2022 at 09:00 CET

Kilde

[Aaleby]

Innsidekjøp av CEO i går, melding og 20% opp i dag

Klassisk Life. Tillitsvekkende som alltid.

[torsteinius]

Det er vel ulovlig? Han forrige pleide alltid å selge dagen etter meldinger.

Får se om han selger igjen imorgen da, hvis aksjen går et stykke?

[Aaleby]

@torsteinius

Det er vel ulovlig?

Prøver vel muligens å gjemme seg bak denne:

@TekBot

In the late hours of June 1st, 2022, the team at Lifecare NanoBioSenors concluded successful

Men det fremstår vel som åpenbart at han må ha visst noe. Så ja, shady så det holder.

[torsteinius]

Eller kanskje han bare hadde jævlig flaks (Sannsynlig)

[Kallep]

Holte i LC og Horpestad i Elop er av samme ulla. Beveger seg heile tida i gråsoner og sitter til slutt igjen som den einaste vinnaren, sammen med nokre andre “nære og nyttige idioter”.

[torsteinius]

Kanskje vi trenger en liste med shady folk og selskaper her på forumet.

Finansdirektøren i B2Holding solgte igjen etter at hun fant ut/kom på at det kunne bli tolket som hun kjøpte på innsideinformasjon. Så kjøpte hun på nytt etter at børsmeldingen var publisert. Så, man kan jo tolke det dit hen at Joacim Holter ønsker å tjene penger innsideinformasjon og ikke på å drive selskapet fremover.

[Halleluja]

Er for tiden i det store utland, men drittlukta fra ledelsen i det selskapet lukter helt hit.

[Halleluja]

Men, kanskje man like gjerne kan gjøre litt penger på denne aksjen da, for man skal ikke undervurdere hvor dumme/uvitende mange folk faktisk er.